Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corporation (Nasdaq: OPRX) regularly issues news and updates about its healthcare technology platform, partnerships, and financial performance. Company press releases describe OptimizeRx as a healthcare technology company that helps life science brands reach and engage healthcare professionals (HCPs) and patients through AI-driven tools, point-of-care integrations, and proprietary audience data.
News items for OptimizeRx often cover collaborations with other data and media companies, such as integrations that connect its patented Micro-Neighborhood® audience data with external identity graphs or out-of-home advertising networks. These announcements explain how the company’s privacy-safe, deterministic audience cohorts are used to support omnichannel and direct-to-consumer campaigns, improve audience quality, and reduce audience loss during onboarding and activation.
Investors and observers will also find earnings releases and guidance updates among OptimizeRx news. These releases include discussions of revenue trends, profitability metrics, key performance indicators related to top pharmaceutical manufacturers, and commentary from management about the company’s progress toward its strategic objectives. Conference call announcements and investor conference participation are also common topics, providing details on how to access management’s discussions of quarterly and annual results.
Additional news highlights may include expansions of the company’s in-workflow point-of-care network through new or renewed agreements with electronic health record (EHR) vendors, e-prescribing platforms, and health systems access partners. Leadership updates and organizational changes are reported through current reports and associated press releases, outlining adjustments in executive roles and governance. For anyone following OPRX, this news page serves as a central source for official company communications on partnerships, technology developments, financial results, and corporate governance.
OptimizeRx (NASDAQ:OPRX), a healthcare technology solutions provider, has announced significant leadership team advancements to accelerate its Rule of 40 strategy, which focuses on balancing growth with increased profitability.
Key appointments include: Ed Stelmakh as Chief Financial & Strategic Officer, Theresa Greco continuing as Chief Commercial Officer, Marion Odence-Ford as Chief Legal & Administrative Officer, Doug Besch as Chief Product & Technology Officer, Brendan Merrell as Chief Operating Officer, and Andy D'Silva as Chief Business Officer.
Under CEO Steve Silvestro's leadership, these organizational changes aim to enhance execution speed, strategic clarity, and drive the company's goal of achieving Rule of 40 in the next 2-3 years while transitioning to a recurring revenue model.
OptimizeRx (NASDAQ:OPRX) reported strong Q2 2025 financial results, with revenue increasing 55% year-over-year to $29.2 million. The company achieved significant improvements in profitability, posting a GAAP net income of $1.5 million ($0.08 per share) compared to a loss of $4.0 million in Q2 2024.
Gross profit rose 59% to $18.6 million, while Adjusted EBITDA reached $5.8 million, up from $0.5 million year-over-year. The company strengthened its financial position by paying down $4.5 million of principal on its outstanding term loan, $4.0 million above schedule.
Based on strong performance, OptimizeRx raised its full-year 2025 guidance, now expecting revenue between $104-108 million and Adjusted EBITDA between $14.5-17.5 million.
Paynela, an AI-driven healthcare financing company, has appointed William Febbo to its Board of Directors. Febbo, the former CEO of OptimizeRX (NASDAQ: OPRX) from 2016 to 2025, brings over 30 years of healthcare technology experience to the role.
During his tenure at OptimizeRX, Febbo transformed the company into a comprehensive omnichannel platform serving top pharmaceutical companies. He currently serves as Office of the Chairman at Oxbridge Health and on the Board of Directors at LifeMD. The appointment comes as Paynela, recently named a 2024 AWS Generative AI Trailblazer, has achieved a 320x increase in processing speed through its AI-driven healthcare data review platform.
OptimizeRx (NASDAQ: OPRX), a healthcare technology solutions provider, has appointed CEO Steve Silvestro to its Board of Directors, effective June 20, 2025. Silvestro, who joined the company in 2019, has served as CEO since March 2025, following his interim CEO role from January 2025.
Under Silvestro's leadership, the company has made significant progress in strengthening its market position. His strategic focus includes enhancing customer experiences, deepening pharmaceutical partnerships, transitioning to a recurring revenue model, and advancing toward Rule of 40 performance. Board Chairperson Lynn Vos expressed confidence in Silvestro's leadership and the company's foundation for long-term value creation.
OptimizeRx (NASDAQ: OPRX), a healthcare technology solutions provider, has announced its participation in four major investor conferences in May and June 2025. The company will attend:
- B. Riley Securities 25th Annual Investor Conference (May 22) in Marina del Rey, featuring 1x1 meetings and a fireside chat
- Stifel 2025 Boston Cross Sector 1x1 Conference (June 3) at InterContinental Boston
- 45th Annual William Blair Growth Stock Conference (June 5) at Loews Chicago Hotel
- The Citizens Medical Devices and Healthcare Services Forum (June 17) at Boston Harbor Hotel
The latter three events will consist of one-on-one meetings with institutional investors.
OptimizeRx (NASDAQ: OPRX) reported strong Q1 2025 financial results with revenue increasing 11% year-over-year to $21.9 million. The company's gross profit grew 9% to $13.3 million, while GAAP net loss improved to $(2.2) million from $(6.9) million in Q1 2024. Non-GAAP net income reached $1.5 million or $0.08 per diluted share.
Notably, OptimizeRx has increased its full-year 2025 guidance, projecting revenue between $101-106 million and adjusted EBITDA between $13-15 million. The company's performance metrics show strong momentum, with year-to-date contracted revenue up over 20% compared to last year. Additionally, OptimizeRx has successfully converted over 5% of expected 2025 sales into subscription-based revenue streams.
OptimizeRx (Nasdaq: OPRX), a leading provider of healthcare technology solutions, has scheduled its first quarter 2025 earnings conference call for Monday, May 12, 2025, at 4:30 p.m. Eastern Time. The company will release its financial results for the period ended March 31, 2025, via press release before the call.
The conference call will include a management presentation followed by a Q&A session. Investors can join through multiple channels including toll-free (1-844-825-9789) and international (1-412-317-5180) numbers. A webcast option is also available, and the replay will be accessible for 12 months through the company's investor relations website.
OptimizeRx (Nasdaq: OPRX) has announced plans to appoint a new independent director to its Board during the second half of 2025, continuing its board refreshment initiative. This appointment will mark the third new director since 2020, following Catherine Klema (2024) and Gregory D. Wasson (2020) additions.
The company, which specializes in healthcare technology solutions connecting life sciences companies with healthcare professionals and patients, is seeking candidates with relevant expertise to complement current Board members and support the company's strategy execution. The Board currently consists of five directors.
Board Chairperson Lynn Vos highlighted the company's progress under new CEO Steve Silvestro, focusing on building market share and driving profitable revenue growth. The company aims to address key pharma challenges including digital brand visibility, reducing script abandonment rates, enhancing point-of-care interoperability, and supporting specialty medications transition.